CAR-T cell therapy in Multiple Myeloma: current status and future challenges

The treatment of multiple myeloma has changed dramatically in recent years, with huge strides forward made in the field. Chimeric antigen receptor T-cell therapy targeting the B cell maturation antigen (BCMA) is now widely approved in relapsed refractory patients and is moving into earlier treatment...

Full description

Saved in:
Bibliographic Details
Published in:Blood cancer journal (New York) 2024-11, Vol.14 (1), p.206-16, Article 206
Main Authors: Swan, Dawn, Madduri, Deepu, Hocking, Jay
Format: Article
Language:English
Subjects:
631/67/327
692/699/67/1990/804
Antigens
B-Cell Maturation Antigen - antagonists & inhibitors
B-Cell Maturation Antigen - immunology
Biomedical and Life Sciences
Biomedicine
Cancer Research
Cancer therapies
Cells
Cytokine storm
FDA approval
Hematology
Humans
Immunotherapy, Adoptive - adverse effects
Immunotherapy, Adoptive - methods
Lymphocytes
Monoclonal antibodies
Multiple myeloma
Multiple Myeloma - therapy
Neurotoxicity
Oncology
Receptors, Chimeric Antigen - immunology
Receptors, Chimeric Antigen - therapeutic use
Regulatory approval
Remission (Medicine)
Review
Review Article
Standard of care
T-Lymphocytes - immunology
Transplants & implants
Tumor Microenvironment - immunology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c422t-f1e86bfac1ccffa506942f5a45d91df26c54cf2f7e32862cf42914f41969b2593
container_end_page 16
container_issue 1
container_start_page 206
container_title Blood cancer journal (New York)
container_volume 14
creator Swan, Dawn
Madduri, Deepu
Hocking, Jay
description The treatment of multiple myeloma has changed dramatically in recent years, with huge strides forward made in the field. Chimeric antigen receptor T-cell therapy targeting the B cell maturation antigen (BCMA) is now widely approved in relapsed refractory patients and is moving into earlier treatment lines. In this review, we discuss the evidence underpinning current regulatory approvals and consider mechanisms through which CAR-T cell efficacy could be improved. These include tackling BCMA-loss, harnessing the immunosuppressive tumour microenvironment, manufacturing concerns including the potential role of other cellular sources, safety issues such as cytokine release syndrome and neurotoxicity, and optimal patient selection.
doi_str_mv 10.1038/s41408-024-01191-8
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_7b721ddf2a9448bfa9e190880a45fd41</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_7b721ddf2a9448bfa9e190880a45fd41</doaj_id><sourcerecordid>3133415496</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-f1e86bfac1ccffa506942f5a45d91df26c54cf2f7e32862cf42914f41969b2593</originalsourceid><addsrcrecordid>eNp9kctuEzEUhkcIRKvSF2CBLLFhM-Djy4zNBlURl0qpkFBZW47HTiZyxsGXSnl7nEwpLQu8seXznf9c_qZ5Dfg9YCo-JAYMixYT1mIACa141pwTzFjLqeDPH73PmsuUtrge3lVQvmzOqOSScNmfN8vF1Y_2FhnrPcobG_X-gMYJ3RSfx7236OZgfdjpj8iUGO2UUco6l4T0NCBXcokWmY323k5rm141L5z2yV7e3xfNzy-fbxff2uX3r9eLq2VrGCG5dWBFt3LagDHOaY47yYjjmvFBwuBIZzgzjrjeUiI6YhwjEphjIDu5qm3Ti-Z61h2C3qp9HHc6HlTQozp9hLhWOubReKv6VU9gqKJaMiZqUWlBYiFwreYGBlXr06y1L6udHUydMWr_RPRpZBo3ah3uFACXkopjN-_uFWL4VWzKajem40L1ZENJigKlDDiTXUXf_oNuQ4lT3dWJwh3rgVSKzJSJIaVo3UM3gNXRfDWbr6r56mS-EjXpzeM5HlL-WF0BOgOphqpb8W_t_8j-BkKKuWE</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3133064712</pqid></control><display><type>article</type><title>CAR-T cell therapy in Multiple Myeloma: current status and future challenges</title><source>Publicly Available Content Database</source><source>PubMed Central</source><source>Coronavirus Research Database</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Swan, Dawn ; Madduri, Deepu ; Hocking, Jay</creator><creatorcontrib>Swan, Dawn ; Madduri, Deepu ; Hocking, Jay</creatorcontrib><description>The treatment of multiple myeloma has changed dramatically in recent years, with huge strides forward made in the field. Chimeric antigen receptor T-cell therapy targeting the B cell maturation antigen (BCMA) is now widely approved in relapsed refractory patients and is moving into earlier treatment lines. In this review, we discuss the evidence underpinning current regulatory approvals and consider mechanisms through which CAR-T cell efficacy could be improved. These include tackling BCMA-loss, harnessing the immunosuppressive tumour microenvironment, manufacturing concerns including the potential role of other cellular sources, safety issues such as cytokine release syndrome and neurotoxicity, and optimal patient selection.</description><identifier>ISSN: 2044-5385</identifier><identifier>EISSN: 2044-5385</identifier><identifier>DOI: 10.1038/s41408-024-01191-8</identifier><identifier>PMID: 39592597</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/67/327 ; 692/699/67/1990/804 ; Antigens ; B-Cell Maturation Antigen - antagonists &amp; inhibitors ; B-Cell Maturation Antigen - immunology ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Cancer therapies ; Cells ; Cytokine storm ; FDA approval ; Hematology ; Humans ; Immunotherapy, Adoptive - adverse effects ; Immunotherapy, Adoptive - methods ; Lymphocytes ; Monoclonal antibodies ; Multiple myeloma ; Multiple Myeloma - therapy ; Neurotoxicity ; Oncology ; Receptors, Chimeric Antigen - immunology ; Receptors, Chimeric Antigen - therapeutic use ; Regulatory approval ; Remission (Medicine) ; Review ; Review Article ; Standard of care ; T-Lymphocytes - immunology ; Transplants &amp; implants ; Tumor Microenvironment - immunology</subject><ispartof>Blood cancer journal (New York), 2024-11, Vol.14 (1), p.206-16, Article 206</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2024 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c422t-f1e86bfac1ccffa506942f5a45d91df26c54cf2f7e32862cf42914f41969b2593</cites><orcidid>0000-0003-1374-7333</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3133064712/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3133064712?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,38493,43871,44566,53766,53768,74155,74869</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39592597$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Swan, Dawn</creatorcontrib><creatorcontrib>Madduri, Deepu</creatorcontrib><creatorcontrib>Hocking, Jay</creatorcontrib><title>CAR-T cell therapy in Multiple Myeloma: current status and future challenges</title><title>Blood cancer journal (New York)</title><addtitle>Blood Cancer J</addtitle><addtitle>Blood Cancer J</addtitle><description>The treatment of multiple myeloma has changed dramatically in recent years, with huge strides forward made in the field. Chimeric antigen receptor T-cell therapy targeting the B cell maturation antigen (BCMA) is now widely approved in relapsed refractory patients and is moving into earlier treatment lines. In this review, we discuss the evidence underpinning current regulatory approvals and consider mechanisms through which CAR-T cell efficacy could be improved. These include tackling BCMA-loss, harnessing the immunosuppressive tumour microenvironment, manufacturing concerns including the potential role of other cellular sources, safety issues such as cytokine release syndrome and neurotoxicity, and optimal patient selection.</description><subject>631/67/327</subject><subject>692/699/67/1990/804</subject><subject>Antigens</subject><subject>B-Cell Maturation Antigen - antagonists &amp; inhibitors</subject><subject>B-Cell Maturation Antigen - immunology</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Cancer therapies</subject><subject>Cells</subject><subject>Cytokine storm</subject><subject>FDA approval</subject><subject>Hematology</subject><subject>Humans</subject><subject>Immunotherapy, Adoptive - adverse effects</subject><subject>Immunotherapy, Adoptive - methods</subject><subject>Lymphocytes</subject><subject>Monoclonal antibodies</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - therapy</subject><subject>Neurotoxicity</subject><subject>Oncology</subject><subject>Receptors, Chimeric Antigen - immunology</subject><subject>Receptors, Chimeric Antigen - therapeutic use</subject><subject>Regulatory approval</subject><subject>Remission (Medicine)</subject><subject>Review</subject><subject>Review Article</subject><subject>Standard of care</subject><subject>T-Lymphocytes - immunology</subject><subject>Transplants &amp; implants</subject><subject>Tumor Microenvironment - immunology</subject><issn>2044-5385</issn><issn>2044-5385</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9kctuEzEUhkcIRKvSF2CBLLFhM-Djy4zNBlURl0qpkFBZW47HTiZyxsGXSnl7nEwpLQu8seXznf9c_qZ5Dfg9YCo-JAYMixYT1mIACa141pwTzFjLqeDPH73PmsuUtrge3lVQvmzOqOSScNmfN8vF1Y_2FhnrPcobG_X-gMYJ3RSfx7236OZgfdjpj8iUGO2UUco6l4T0NCBXcokWmY323k5rm141L5z2yV7e3xfNzy-fbxff2uX3r9eLq2VrGCG5dWBFt3LagDHOaY47yYjjmvFBwuBIZzgzjrjeUiI6YhwjEphjIDu5qm3Ti-Z61h2C3qp9HHc6HlTQozp9hLhWOubReKv6VU9gqKJaMiZqUWlBYiFwreYGBlXr06y1L6udHUydMWr_RPRpZBo3ah3uFACXkopjN-_uFWL4VWzKajem40L1ZENJigKlDDiTXUXf_oNuQ4lT3dWJwh3rgVSKzJSJIaVo3UM3gNXRfDWbr6r56mS-EjXpzeM5HlL-WF0BOgOphqpb8W_t_8j-BkKKuWE</recordid><startdate>20241126</startdate><enddate>20241126</enddate><creator>Swan, Dawn</creator><creator>Madduri, Deepu</creator><creator>Hocking, Jay</creator><general>Nature Publishing Group UK</general><general>Springer Nature B.V</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-1374-7333</orcidid></search><sort><creationdate>20241126</creationdate><title>CAR-T cell therapy in Multiple Myeloma: current status and future challenges</title><author>Swan, Dawn ; Madduri, Deepu ; Hocking, Jay</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-f1e86bfac1ccffa506942f5a45d91df26c54cf2f7e32862cf42914f41969b2593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>631/67/327</topic><topic>692/699/67/1990/804</topic><topic>Antigens</topic><topic>B-Cell Maturation Antigen - antagonists &amp; inhibitors</topic><topic>B-Cell Maturation Antigen - immunology</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Cancer therapies</topic><topic>Cells</topic><topic>Cytokine storm</topic><topic>FDA approval</topic><topic>Hematology</topic><topic>Humans</topic><topic>Immunotherapy, Adoptive - adverse effects</topic><topic>Immunotherapy, Adoptive - methods</topic><topic>Lymphocytes</topic><topic>Monoclonal antibodies</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - therapy</topic><topic>Neurotoxicity</topic><topic>Oncology</topic><topic>Receptors, Chimeric Antigen - immunology</topic><topic>Receptors, Chimeric Antigen - therapeutic use</topic><topic>Regulatory approval</topic><topic>Remission (Medicine)</topic><topic>Review</topic><topic>Review Article</topic><topic>Standard of care</topic><topic>T-Lymphocytes - immunology</topic><topic>Transplants &amp; implants</topic><topic>Tumor Microenvironment - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Swan, Dawn</creatorcontrib><creatorcontrib>Madduri, Deepu</creatorcontrib><creatorcontrib>Hocking, Jay</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Blood cancer journal (New York)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Swan, Dawn</au><au>Madduri, Deepu</au><au>Hocking, Jay</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CAR-T cell therapy in Multiple Myeloma: current status and future challenges</atitle><jtitle>Blood cancer journal (New York)</jtitle><stitle>Blood Cancer J</stitle><addtitle>Blood Cancer J</addtitle><date>2024-11-26</date><risdate>2024</risdate><volume>14</volume><issue>1</issue><spage>206</spage><epage>16</epage><pages>206-16</pages><artnum>206</artnum><issn>2044-5385</issn><eissn>2044-5385</eissn><abstract>The treatment of multiple myeloma has changed dramatically in recent years, with huge strides forward made in the field. Chimeric antigen receptor T-cell therapy targeting the B cell maturation antigen (BCMA) is now widely approved in relapsed refractory patients and is moving into earlier treatment lines. In this review, we discuss the evidence underpinning current regulatory approvals and consider mechanisms through which CAR-T cell efficacy could be improved. These include tackling BCMA-loss, harnessing the immunosuppressive tumour microenvironment, manufacturing concerns including the potential role of other cellular sources, safety issues such as cytokine release syndrome and neurotoxicity, and optimal patient selection.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>39592597</pmid><doi>10.1038/s41408-024-01191-8</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0003-1374-7333</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2044-5385
ispartof Blood cancer journal (New York), 2024-11, Vol.14 (1), p.206-16, Article 206
issn 2044-5385
2044-5385
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_7b721ddf2a9448bfa9e190880a45fd41
source Publicly Available Content Database; PubMed Central; Coronavirus Research Database; Springer Nature - nature.com Journals - Fully Open Access
subjects 631/67/327
692/699/67/1990/804
Antigens
B-Cell Maturation Antigen - antagonists & inhibitors
B-Cell Maturation Antigen - immunology
Biomedical and Life Sciences
Biomedicine
Cancer Research
Cancer therapies
Cells
Cytokine storm
FDA approval
Hematology
Humans
Immunotherapy, Adoptive - adverse effects
Immunotherapy, Adoptive - methods
Lymphocytes
Monoclonal antibodies
Multiple myeloma
Multiple Myeloma - therapy
Neurotoxicity
Oncology
Receptors, Chimeric Antigen - immunology
Receptors, Chimeric Antigen - therapeutic use
Regulatory approval
Remission (Medicine)
Review
Review Article
Standard of care
T-Lymphocytes - immunology
Transplants & implants
Tumor Microenvironment - immunology
title CAR-T cell therapy in Multiple Myeloma: current status and future challenges
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T02%3A43%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CAR-T%20cell%20therapy%20in%20Multiple%20Myeloma:%20current%20status%20and%20future%20challenges&rft.jtitle=Blood%20cancer%20journal%20(New%20York)&rft.au=Swan,%20Dawn&rft.date=2024-11-26&rft.volume=14&rft.issue=1&rft.spage=206&rft.epage=16&rft.pages=206-16&rft.artnum=206&rft.issn=2044-5385&rft.eissn=2044-5385&rft_id=info:doi/10.1038/s41408-024-01191-8&rft_dat=%3Cproquest_doaj_%3E3133415496%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c422t-f1e86bfac1ccffa506942f5a45d91df26c54cf2f7e32862cf42914f41969b2593%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3133064712&rft_id=info:pmid/39592597&rfr_iscdi=true